Gagandeep Kang

Employment

• Christian Medical College, Vellore Professor of Microbiology
  2000 - Present
• Christian Medical College, Vellore Assocaite Professor of Microbiology
  1996 - 2000
• Christian Medical College, Vellore Assistant Professor of Microbiology
  1991 - 1996

Education

• Christian Medical College and Hospital Vellore PhD
  1992 - 1998
• Christian Medical College and Hospital Vellore MD
  1988 - 1991
• Christian Medical College and Hospital Vellore MBBS
  1981 - 1987

Projects & Funding

Projects & funding information is unavailable.

Publications (143)

• Drinking water quality and incidence of Diarrhoea in children aged 6 months to 15 years: Findings from a paediatric cohort in Vellore, Southern India
  2026 DOI: 10.64898/2026.01.13.26344065
  +Save
• Effectiveness of an Indigenous Pentavalent, Live Attenuated, Oral Rotavirus Vaccine ROTASIIL® among Children Younger than 2 Years of Age Hospitalized with Acute Gastroenteritis in Seven States of India: 2019-2023
  2025 DOI: 10.21203/rs.3.rs-7329576/v1
  +Save
• Interventions in adult patients with multimorbidity in low-income and middle-income countries: protocol for a mixed-methods systematic review
  BMJ Open 2024 DOI: 10.1136/bmjopen-2023-074038
  +Save
• Post-marketing safety surveillance of the rotavirus vaccine in India
  Vaccine: X 2023 DOI: 10.1016/j.jvacx.2023.100362
  +Save
• Environmental surveillance for Salmonella Typhi and its association with typhoid fever incidence in India and Malawi
  2023 DOI: 10.1093/infdis/jiad427
  +Save
• Association Between Maternal Breastmilk Microbiota Composition and Rotavirus Vaccine Response in African, Asian, and European Infants: A Prospective Cohort Study
  The Journal of Infectious Diseases 2023 DOI: 10.1093/infdis/jiad234
  +Save
• Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city
  Nature Communications 2023 DOI: 10.1038/s41467-023-39322-7
  +Save
• Development of a Choice-framework for Covid vaccines in India using a multi-criteria decision analysis approach
  Vaccine 2023 DOI: 10.1016/j.vaccine.2023.04.062
  +Save
• Overstated conclusions of a non-inferiority trial testing immunogenicity and safety of homologous and heterologous booster – authors' reply
  The Lancet Regional Health - Southeast Asia 2023 DOI: 10.1016/j.lansea.2023.100204
  +Save
• Vaccines and therapeutics for immunocompromised patients with COVID-19
  eClinicalMedicine 2023 DOI: 10.1016/j.eclinm.2023.101965
  +Save